Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean‐Jacques Kiladjian,
Pierre Zachée,
Masayuki Hino,
Fabrizio Pane,
Tamás Masszi,
Claire Harrison,
Ruben A. Mesa,
Carole B. Miller,
Francesco Passamonti,
Simon Durrant,
The Lancet Haematology · 2020 · 142 citations · 16 references